Opiant Pharmaceuticals, Inc. (OPNT) |
| 20.65 0 (0%) 03-01 16:00 |
| Open: | 20.8765 |
| High: | 20.94 |
| Low: | 20.56 |
| Volume: | 562,778 |
| Market Cap: | 109(M) |
| PE Ratio: | -3.16 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 27.36 |
| 52w Low: | 7.34 |
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Thu, 02 Mar 2023
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc. - PR Newswire
Fri, 13 Jan 2023
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In (NASDAQ:OPNT) - Seeking Alpha
Mon, 14 Nov 2022
Indivior To Acquire Opiant Pharmaceuticals - PR Newswire
Mon, 14 Nov 2022
Watkins Advises Opiant Pharmaceuticals in Sale to Indivior PLC - Latham & Watkins LLP
Sun, 13 Nov 2022
Indivior PLC to Acquire Opiant Pharmaceuticals - Yahoo Finance
Sun, 07 Jun 2020
Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
